rs121918389 — APOB Q1477X (apoB-32)

APOB Q1477X — The ApoB-32 Truncation and Familial Hypobetalipoproteinemia

Apolipoprotein B (apoB) is the indispensable structural protein of atherogenic lipoproteins — LDL, VLDL, and IDL. Every LDL particle contains exactly one molecule of apoB-100, a 4,536-amino-acid protein that serves both as the scaffolding for lipoprotein assembly in the liver and as the docking ligand for LDL receptor recognition. When rs121918389 introduces a premature stop codon at position 1477 (Q1477X), the result is apoB-32 — a truncated protein containing only the first 1,476 amino acids of apoB-100, representing just 32% of the full-length protein. This truncation defines one of the founding mutations of familial hypobetalipoproteinemia (FHBL)¹¹ familial hypobetalipoproteinemia (FHBL)
FHBL is a disorder of very low LDL and apoB levels caused by APOB loss-of-function mutations; OMIM 615558.

The Mechanism

The p.Gln1477Ter stop-gain eliminates the C-terminal two-thirds of apoB-100, including the LDL receptor-binding domain (located between residues ~3000–3500). McCormick et al.²² McCormick et al.
McCormick et al. Apolipoprotein B-32: a new truncated mutant of human apolipoprotein B capable of forming particles in the low density lipoprotein range. Biochim Biophys Acta, 1992 showed that apoB-32 is remarkably unusual among short apoB truncations: it is the shortest known apoB variant capable of forming particles in the LDL density range. However, the majority of apoB-32 partitioned to the HDL and lipoprotein-depleted (d>1.21 g/mL) fractions, with only trace amounts appearing in LDL and none detected in VLDL. This means the liver cannot assemble and secrete apoB-32 as functional VLDL particles, causing hepatic fat accumulation while simultaneously depriving the circulation of its normal complement of LDL cholesterol.

In heterozygotes, one APOB allele produces full-length apoB-100 and the other produces apoB-32. The result is approximately 50% reduction in circulating LDL-C and apoB concentrations compared to unaffected individuals. Because apoB-32 is shorter than apoB-48 (the intestinal isoform that terminates at residue 2152), the intestinal chylomicron pathway is preserved through the wild-type allele — heterozygotes retain fat absorption capacity, which is why severe nutritional deficiency is uncommon in this group.

The Evidence

GeneReviews on APOB-FHBL³³ GeneReviews on APOB-FHBL
Burnett, Hooper, Hegele. APOB-Related Familial Hypobetalipoproteinemia. GeneReviews, 2021 summarizes the clinical spectrum: heterozygotes have plasma LDL-C typically below the 5th percentile for age and sex (~3.0 mmol/L or 115 mg/dL), with LDL-C and apoB concentrations approximately one-third of normal. Heterozygotes are usually asymptomatic, though hepatic steatosis — with a three- to five-fold increase in hepatic fat content versus population norms — is common. About 5–10% of heterozygous carriers develop nonalcoholic steatohepatitis (NASH) that may require medical attention; cirrhosis is rare.

Paradoxically, heterozygous APOB-FHBL confers protection against atherosclerotic cardiovascular disease due to lifelong reductions in LDL cholesterol. This mirrors the cardiovascular protection observed with PCSK9 loss-of-function variants and statin therapy — reinforcing that lower LDL, even when caused by a truncating variant, is cardioprotective.

Tarugi et al. 2001⁴⁴ Tarugi et al. 2001
Tarugi et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. Journal of Lipid Research, 2001 examined apoB truncation length and hepatic outcomes across three kindreds, finding that fatty liver develops invariably in carriers of short and medium truncations (shorter than apoB-48), while longer forms require additional environmental co-factors such as alcohol or metabolic syndrome. The Q1477X mutation producing apoB-32 falls squarely in the "short truncation" category and reliably causes hepatic steatosis.

Practical Actions

For heterozygous carriers (AG genotype), the primary clinical priorities are: (1) confirming the lipid phenotype, (2) monitoring for hepatic steatosis progression, and (3) maintaining fat-soluble vitamin sufficiency. Although heterozygotes rarely develop severe vitamin deficiency, the three- to five-fold increase in hepatic fat indicates that fat absorption and transport are measurably impaired. Monitoring fat-soluble vitamin levels (particularly vitamins E and D) annually is warranted.

Dietary fat intake does not need to be severely restricted in heterozygotes — unlike biallelic FHBL, where a low-fat diet is essential. However, minimizing hepatic fat accumulation by reducing refined carbohydrates and excess dietary fat is reasonable. Alcohol should be minimized, as it is an established hepatic steatosis co-factor.

Interactions

The Q1477X allele interacts in compound heterozygous fashion with other APOB truncating or loss-of-function variants. Compound heterozygosity or homozygosity for APOB truncations produces biallelic FHBL, which resembles abetalipoproteinemia with severe fat malabsorption, fat-soluble vitamin deficiency, and neurological complications if untreated. This is an autosomal recessive severe form requiring aggressive fat-soluble vitamin supplementation and low-fat diet.

The APOB R3527Q variant (rs5742904), which causes familial hypercholesterolemia through defective LDL receptor binding rather than truncation, represents the opposite end of the APOB clinical spectrum — same gene, mechanistically opposite phenotype. Clinicians evaluating unexplained hypocholesterolemia should consider this locus, just as they consider rs5742904 for familial hypercholesterolemia.